Skip to Content

Join the 'Schizophrenia' group to help and get support from people like you.

Schizophrenia News

Related terms: Catatonic Schizophrenia, Disorganized Schizophrenia, Paranoid Schizophrenia, Residual Schizophrenia, Schizophrenia, catatonic, Schizophrenia, disorganized, Schizophrenia, paranoid, Schizophrenia, residual, Schizophrenia, undifferentiated, Undifferentiated Schizophrenia

Mental Illness Afflicts Many Juveniles in Jail

Posted 10 days ago by Drugs.com

TUESDAY, July 21, 2015 – Hospitalization for mental health problems is far more common among kids behind bars than among children and teens in the general population, a new study finds. Juvenile inmates also have longer hospital stays, which suggests they have more serious underlying mental health problems, according to the Stanford University School of Medicine researchers. "We know young people in the juvenile justice system have a disproportionate burden of mental illness, but I was really surprised by the magnitude of the problem, because hospitalizations typically occur for very severe illness," lead author Dr. Arash Anoshiravani, a clinical assistant professor of adolescent medicine, said in a university news release. The researchers analyzed nearly 2 million hospitalizations of children and teens in California over the age of 15. They found that mental health disorders accounted ... Read more

Related support groups: Anxiety, Depression, Generalized Anxiety Disorder, Panic Disorder, Bipolar Disorder, Attention Deficit Hyperactivity Disorder (ADHD), Anxiety and Stress, Social Anxiety Disorder, Major Depressive Disorder, Schizophrenia, Mania, Borderline Personality Disorder, Schizoaffective Disorder, Oppositional Defiant Disorder, Autism, Psychosis, Agitation, Psychiatric Disorders, Agitated State, Asperger Syndrome

Rexulti Approved for Schizophrenia, Depression

Posted 18 days ago by Drugs.com

MONDAY, July 13, 2015 – Rexulti (brexpiprazole) has been approved by the U.S. Food and Drug Administration to treat schizophrenia, and as an add-on drug for major depressive disorder (MDD) when a first-line drug fails to effectively treat symptoms. Schizophrenia is a chronic, disabling brain disorder that primary affects people aged 30 and younger. Affecting about 1 percent of Americans, the disorder is characterized by hearing voices, believing other people are reading your mind, withdrawal and suspicion. MDD, commonly called depression, is characterized by unhappy mood that interferes with a person's ability to carry on life's daily activities. Other symptoms may include loss of interest in daily life, weight change, insomnia, restlessness, fatigue, feeling guilty or worthless, and inability to concentrate. Clinical studies evaluating the drug for both disorders involved more than ... Read more

Related support groups: Depression, Major Depressive Disorder, Schizophrenia, Rexulti, Brexpiprazole

U.S. FDA Approves New Drug Rexulti for Schizophrenia, Major Depression

Posted 18 days ago by Drugs.com

MONDAY, July 13, 2015 – A new drug to treat schizophrenia and depression has been approved by the U.S. Food and Drug Administration. Rexulti (brexpiprazole) tablets can be used to treat adults with schizophrenia. The new drug can also be used as an add-on therapy to antidepressant drugs for adults with major depression. "Schizophrenia and major depressive disorder can be disabling and can greatly disrupt day-to-day activities," Dr. Mitchell Mathis, director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research, said in an agency news release. "Medications affect everyone differently so it is important to have a variety of treatment options available for patients with mental illnesses," he added. The FDA's approval of Rexulti for treatment of schizophrenia is based on two six-week clinical trials with more than 1,300 people. People taking the drug ... Read more

Related support groups: Depression, Major Depressive Disorder, Schizophrenia, Rexulti, Brexpiprazole

FDA Approves Rexulti (brexpiprazole) for Schizophrenia and Adjunctive Treatment for Major Depressive Disorder

Posted 11 Jul 2015 by Drugs.com

Tokyo, Japan and Valby, Denmark – July 11, 2015 –Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced today that the U.S. Food and Drug Administration (FDA) approved Rexulti (brexpiprazole) as an adjunctive therapy for the treatment of adults with major depressive disorder (MDD) and as a treatment for adults with schizophrenia. Rexulti was discovered by Otsuka and co-developed with Lundbeck. It will be co-marketed by the two companies and is expected to become available to patients in the U.S. in early August 2015. The mechanism of action of Rexulti in the treatment of MDD or schizophrenia is unknown. However, the efficacy of Rexulti may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. In addition, Rexulti exhibits high affinity (subnanomolar) ... Read more

Related support groups: Depression, Major Depressive Disorder, Schizophrenia, Rexulti, Brexpiprazole

Early Intervention Shows Promise in Treating Schizophrenia

Posted 8 Jul 2015 by Drugs.com

WEDNESDAY, July 8, 2015 – Interventions that include resiliency training, education and job support may boost the mental health of patients in the early stages of schizophrenia, new research reveals. The finding, reported in the July issue of Psychiatric Services, followed an assessment of several specialty care programs, including some funded through a U.S. National Institute of Mental Health (NIMH) initiative known as RAISE (Recovery After an Initial Schizophrenia Episode). The comprehensive treatment programs also include family education and goal-setting. Investigators found that patients who completed RAISE fared better both socially and on the job. They also showed fewer symptoms and were less likely to relapse. Clinicians credit the program's emphasis on shared decision-making as key to its success, along with a respectful, flexible and warm attitude toward patients by the RAISE ... Read more

Related support groups: Schizophrenia, Schizoaffective Disorder

FDA Approves Invega Trinza (paliperidone palmitate) Four-Times-A-Year Treatment for Schizophrenia

Posted 19 May 2015 by Drugs.com

TITUSVILLE, N.J., May 19, 2015 – There’s a new treatment option for schizophrenia – Invega Trinza (three-month paliperidone palmitate), the first and only schizophrenia medication to be administered just four times a year, providing the longest dosing interval available. Janssen Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved under priority review the New Drug Application (NDA) for the three-month long-acting atypical antipsychotic Invega Trinza. Invega Trinza, a three-month injection, is an atypical antipsychotic indicated to treat schizophrenia. Before starting Invega Trinza, patients must be adequately treated with Invega Sustenna (one-month paliperidone palmitate) for at least four months. Priority review is a designation for drugs that, if approved, would offer significant improvement in the treatment of serious conditions. In a long- ... Read more

Related support groups: Schizophrenia, Invega, Invega Sustenna, Paliperidone

First Generic Abilify Approved

Posted 29 Apr 2015 by Drugs.com

WEDNESDAY, April 29, 2015 – The first generic versions of the atypical antipsychotic drug Abilify (aripiprazole) have been approved by the U.S. Food and Drug Administration to treat schizophrenia or bipolar disorder. License to produce the drug in multiple strengths was approved for Alembic Pharmaceuticals, Hetero Labs, Teva Pharmaceuticals, and Torrent Pharmaceuticals, the agency said in a news release. Bipolar disorder, also known as manic depression or manic-depressive illness, is a brain disorder that causes unusual moods and activities, affecting the ability to carry out day-to-day tasks. Symptoms typically include alternating periods of depression (lows) and increased activity and restlessness (highs). Schizophrenia, another brain disorder, affects about 1 percent of Americans. Symptoms typically begin in people younger than 30, and include hearing voices, believing other people ... Read more

Related support groups: Bipolar Disorder, Seroquel, Abilify, Schizophrenia, Mania, Zyprexa, Risperdal, Risperidone, Geodon, Schizoaffective Disorder, Latuda, Saphris, Seroquel XR, Quetiapine, Olanzapine, Invega, Clozapine, Aripiprazole, Clozaril, Fanapt

FDA Approves First Generic Abilify (aripiprazole) to Treat Mental Illnesses

Posted 28 Apr 2015 by Drugs.com

April 28, 2015 – The U.S. Food and Drug Administration today approved the first generic versions of Abilify (aripiprazole). Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder. Alembic Pharmaceuticals Ltd., Hetero Labs Ltd., Teva Pharmaceuticals and Torrent Pharmaceuticals Ltd. have received FDA approval to market generic aripiprazole in multiple strengths and dosage forms. “Having access to treatments is important for patients with long-term health conditions,” said John Peters, M.D., acting director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research. “Health care professionals and consumers can be assured that FDA-approved generic drugs have met the same rigorous standards as the brand-name drug.” Schizophrenia is a chronic, severe and disabling brain disorder. About one percent of Americans ha ... Read more

Related support groups: Bipolar Disorder, Abilify, Schizophrenia, Aripiprazole, Abilify Discmelt, Abilify Maintena

FDA Medwatch Alert: Zyprexa Relprevv (olanzapine pamoate): Drug Safety Communication - FDA Review of Study Sheds Light on Two Deaths Associated with the Injectable Schizophrenia Drug

Posted 23 Mar 2015 by Drugs.com

ISSUE: FDA has concluded a review of a study undertaken to determine the cause of elevated levels of the injectable schizophrenia drug Zyprexa Relprevv (olanzapine pamoate) in two patients who died. The study results were inconclusive. FDA is unable to exclude the possibility that the deaths were caused by rapid, but delayed, entry of the drug into the bloodstream following intramuscular injection. The study suggested that much of the drug level increase could have occurred after death, a finding that could explain the extremely high blood levels found in the two patients who died 3 to 4 days after receiving injections of appropriate doses of Zyprexa Relprevv. On the basis of all of the information reviewed (refer to the Drug Safety Communication for a full data summary), FDA is not recommending any changes to the current prescribing or use of Zyprexa Relprevv injection at this time. ... Read more

Related support groups: Schizophrenia, Zyprexa, Olanzapine, Zyprexa Relprevv

Study Highlights Complexity of 'Hearing Voices'

Posted 11 Mar 2015 by Drugs.com

WEDNESDAY, March 11, 2015 – Rachel Waddingham hears voices. "I hear about 13 or so voices," she said in a news release from Durham University, in England. "Each of them is different – some have names, they are different ages and sound like different people. Some of them are very angry and violent, others are scared, and others are mischievous." In fact, "for me, the word 'voices' isn't sufficient," said Waddingham, a trustee of the National Hearing Voices Network in the United Kingdom, and the International Society for Psychological and Social Approaches to Psychosis. She said that while she uses the word voices to convey her experience, the word also "hides the embodied parts of my experience for which I have few words to describe." Now, a new study from Durham University highlights the complexity and variety of the "voices" some psychiatric patients and others experience. The study ... Read more

Related support groups: Schizophrenia, Schizoaffective Disorder

Mental Health Disorders May Shorten Life Span: Study

Posted 11 Feb 2015 by Drugs.com

WEDNESDAY, Feb. 11, 2015 – People with mental health conditions such as depression, chronic anxiety and schizophrenia tend to die at younger ages than their peers without psychiatric disorders, a new research review says. In fact, the researchers estimated that mental health disorders typically rob people of nearly a decade of life, and account for 8 million deaths worldwide each year. The findings, published online Feb. 11 in JAMA Psychiatry, come from an analysis of over 200 international studies spanning several decades. Researchers said the studies help put the global toll of mental health disorders into perspective. Although the study found an association between mental health conditions and earlier death, it wasn't designed to prove that the disorders were a direct cause of the early deaths. When people think of lives lost to mental illness, they might automatically focus on one ... Read more

Related support groups: Anxiety, Depression, Schizophrenia, Psychiatric Disorders

FDA Medwatch Alert: Ziprasidone (Marketed as Geodon and Generics): Drug Safety Communication - Rare But Potentially Fatal Skin Reactions

Posted 11 Dec 2014 by Drugs.com

ISSUE:  FDA is warning that the antipsychotic drug ziprasidone (marketed under the brand name, Geodon, and its generics) is associated with a rare but serious skin reaction that can progress to affect other parts of the body. A new warning has been added to the Geodon drug label to describe the serious condition known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). See the FDA Drug Safety Communication for a Data Summary and additional information. DRESS may start as a rash that can spread to all parts of the body. It can include fever, swollen lymph nodes, and inflammation of organs such as the liver, kidney, lungs, heart, or pancreas. DRESS also causes a higher-than-normal number of a particular type of white blood cell called eosinophils in the blood. DRESS can lead to death. BACKGROUND: Ziprasidone is an atypical antipsychotic drug used to treat schizophrenia and ... Read more

Related support groups: Bipolar Disorder, Schizophrenia, Geodon, Ziprasidone

FDA Approves Labeling Update Of Abilify Maintena for Acutely Relapsed Adults With Schizophrenia

Posted 10 Dec 2014 by Drugs.com

Tokyo, Japan and Valby, Denmark – December 6, 2014 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced that the U.S. Food and Drug Administration (FDA) approved the labeling update of Abilify Maintena (aripiprazole) for extended-release injectable suspension. The approval was based on results from a controlled clinical study of acutely relapsed adults with schizophrenia. Efficacy was demonstrated in a 12-week randomized, double-blind, placebo-controlled study, which showed treatment with Abilify Maintena (with concomitant oral aripiprazole for the first two weeks) significantly improved symptoms with an acceptable safety and tolerability profile in adult patients experiencing an acute relapse of schizophrenia.1 These data were published in the November print edition of The Journal of Clinical Psychiatry. 2 Abilify Maintena, an atypical antipsychotic, was ... Read more

Related support groups: Abilify, Schizophrenia, Aripiprazole, Abilify Maintena

Study Finds Need for Improved Schizophrenia Care

Posted 8 Dec 2014 by Drugs.com

THURSDAY, Dec. 4, 2014 – Improper drug treatment is given to nearly 40 percent of people who suffer their first episode of schizophrenia, according to a new study. Because schizophrenia is typically a chronic illness, early treatment can have an effect on a patient's long-term outcome, the researchers noted. Inappropriate drug treatment can lead to problems that cause patients to stop taking their medication. The study included 404 people who suffered a first episode of schizophrenia. They were seen at community treatment centers in 21 states. Of those patients, 159 received drug treatment that was inconsistent with recommendations for first-episode patients. Some of the more common mistakes the researchers cited included: Prescribing more than one antipsychotic drug. A higher-than-recommended dose of an antipsychotic. The use of psychotropic medication other than an antipsychotic. ... Read more

Related support groups: Schizophrenia

FDA Approves Dual-Chamber Syringe for Abilify Maintena (aripiprazole) for Schizophrenia

Posted 1 Oct 2014 by Drugs.com

Princeton, N.J. and Deerfield, Ill. – September 29, 2014 – Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) has approved a new formulation of Abilify Maintena (aripiprazole) for extended-release injectable suspension – a pre-filled dual-chamber syringe. Abilify Maintena is an atypical antipsychotic indicated for the treatment of schizophrenia; efficacy was demonstrated in a placebo-controlled, randomized-withdrawal maintenance trial in patients with schizophrenia and additional support for efficacy was derived from oral aripiprazole trials. The companies expect the dual-chamber syringe will be available in the U.S. in January 2015. “Since March 2013, Abilify Maintena has been an important treatment option for people living with schizophrenia. Otsuka and Lundbeck continue to be committed to ... Read more

Related support groups: Abilify, Schizophrenia, Aripiprazole, Abilify Maintena

Page 1 2 3 4 5 6 Next

Ask a Question

Further Information

Related Condition Support Groups

Schizoaffective Disorder, Psychiatric Disorders

Related Drug Support Groups

Seroquel, Abilify, Zyprexa, Risperdal, risperidone, Geodon, Latuda, Saphris, Seroquel XR, view more... quetiapine, olanzapine, Invega, clozapine, aripiprazole, Thorazine, Clozaril, Fanapt, ziprasidone, Invega Sustenna, chlorpromazine, Zyprexa Zydis, paliperidone, asenapine, Risperdal Consta, Stelazine, thioridazine, Mellaril, loxapine, trifluoperazine, iloperidone, Loxitane, Risperdal M-Tab, lurasidone, Denzapine, Clopine, Zyprexa Intramuscular, reserpine, Abilify Discmelt, Abilify Maintena, Rexulti, Versacloz, Invega Trinza, Zyprexa Relprevv, Adasuve, FazaClo, Ormazine, mesoridazine, brexpiprazole, molindone, Clozapine Synthon, Zaponex, Loxitane C, Serentil, Mellaril-S, Loxitane IM